Abstract
We read with interest the article by Shahin and colleagues [1] in the previous issue of Critical Care. Th e authors suggested, in a retrospective analysis, that dobutamine use in patients undergoing cardiac surgery was independently associated with a 2.3-fold increase in mortality and a 2.7-fold increase in risk of renal dysfunction. We have some concerns regarding this conclusion. Th e primary concern with this analysis is the choice of covariates included in the multivariable logistic regression. Th ese were not derived from a univariate analysis. Also, co-variates included in the logistic regression were diff erent from variables used in the matching propensity analysis. In the matching analysis, the ejection fraction (EF) in the group exposed to dobutamine was signifi cantly lower than the EF in the other patients, and this may have contributed to worse outcomes. So, these potential biases are of concern, especially when we consider that these results are inconsistent with the daily routine practice of cardiac surgery in many centers. In a recent commentary, Singer and Brealey [2] argued that, other than dobutamine, current options to improve the hemodynamic status of critically ill patients are relatively limited. After cardiac surgery, this is even more true, as the vasodilation frequently present in these patients can limit the use of other inodilators like levosimendan and milrinone [3]. Pharmacological support for low cardiac output is often required during and after weaning from cardiopulmonary bypass [4]. During this early postoperative period, optimization of cardiac output is needed to prevent complications, and dobutamine is the drug of choice because of its good tolerance and safety [5]. New agents are being evaluated, but dobutamine is still the inotropic of choice in patients undergoing cardiac surgery [4]. Although this study suggests that dobutamine may increase morbidity and mortality after cardiac surgery [1], there is no reason to ban dobutamine after cardiac surgery, as it may still be more benefi cial than harmful.
Highlights
We read with interest the article by Shahin and colleagues [1] in the previous issue of Critical Care
Pharmacological support for low cardiac output is often required during and after weaning from cardiopulmonary bypass [4]. During this early postoperative period, optimization of cardiac output is needed to prevent complications, and dobutamine is the drug of choice because of its good tolerance and safety [5]
This study suggests that dobutamine may increase morbidity and mortality after cardiac surgery [1], there is no reason to ban dobutamine after cardiac surgery, as it may still be more beneficial than harmful
Summary
We read with interest the article by Shahin and colleagues [1] in the previous issue of Critical Care. Singer and Brealey [2] argued that, other than dobutamine, current options to improve the hemodynamic status of critically ill patients are relatively limited. This is even more true, as the vasodilation frequently present in these patients can limit the use of other inodilators like levosimendan and milrinone [3]. Pharmacological support for low cardiac output is often required during and after weaning from cardiopulmonary bypass [4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
